2 Result: Nasdaq:TARS
Buy Ratings: TARS, VICR, SNDX, ENLC, AMZN, UFPT, PEN - Key Upside Potential
June 26th, 2023
Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS), a biopharmaceutical company specializing in ophthalmic therapeutics, has been maintained at a Buy rating by HC Wainwright & Co., who raised the price target from $40 to $44. $TARS closed at $17.15. Read more
Market Buzz: Bullish Narrative for Liquid Media, Tarsus Pharma, Vertiv, and Neogen
June 17th, 2023
Shares of Liquid Media Group Ltd. (Nasdaq: YVR) experienced a notable surge of over 11% in after-hours trading Friday as the company revealed the sale of its wholly-owned subsidiary, IndieFlix Group, for a total purchase price of US$1.2 million. T. Read more
Want To Find Some News?
News By Industries
Recent Post
-
NVIDIA, Salesforce, and Agilent Technologies Earnings Loom: What to Expect
February 23rd, 2025Key Reports Ahead: KBR, Hims & Hers Health, and Cleveland-Cliffs Earnings Preview
February 23rd, 2025Earnings On Deck: What to Expect from Copart, Cheniere Energy, and Insulet
February 16th, 2025Earnings Preview: Amicus Therapeutics, ANSYS, and Etsy Take Center Stage
February 16th, 2025
Member Login